Motexafin gadolinium: a novel radiosensitizer for brain tumors

Forouzannia, Afshin; Richards, Gregory M.; Khuntia, Deepak; Mehta, Minesh P.

doi:10.1586/14737140.7.6.785

Cited by 23 publications

(17 citation statements)

References 42 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Phase III trial evaluated the use of BUdR in patients with anaplastic astrocytoma. BUdR, however, did not significantly extend survival (4.1 versus 4.6 years for non-BUdR and BUdR patients, respectively (p = 0.61)) [9].…”

Section: Introductionmentioning

confidence: 79%

“…Classic chemotherapeutic drugs such as the fluoropyrimidines have also been found to demonstrate radiosensitization of tumor cells through their effect on nucleoside and nucleotide metabolism [9,14]. Their mechanism of action prevents cells from entering S Phase, a typically radiation-resistant stage during the cell cycle [9].…”

Section: Introductionmentioning

confidence: 99%

“…Their mechanism of action prevents cells from entering S Phase, a typically radiation-resistant stage during the cell cycle [9]. Gemcitabine, another common cytotoxic agent often used in lung cancer and gastrointestinal tumors, is a potent radiation sensitizer.…”

Section: Introductionmentioning

confidence: 99%

“…Recent Phase I, II and III trials have shown that motexafin gadolinium (MGd) (Box 1) is selectively taken up by tumor cells and may increase the therapeutic ratio in managing brain metastases [9]. In this paper, we further describe the rationale for MGd use in the management of brain metastases as well as investigate its current and future use as a radiation sensitizer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Motexafin gadolinium: a novel radiosensitizer for brain tumors

Francis¹,

Richards²,

Forouzannia

et al. 2009

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

For a variety of reasons, the management of brain tumors, both primary and metastatic, remains a considerable challenge. As most systemic therapies do not cross the BBB at therapeutic doses, radiation and surgery have played primary roles in the management of these diseases. Despite significant advances in surgical techniques and radiation delivery, outcomes for most adult brain tumors continue to be poor. In an effort to enhance the effects of radiation in the brain, a variety of radiation sensitizers, including motexafin gadolinium, have been investigated. In the following manuscript, we summarize motexafin gadolinium and its role in brain tumors.

show abstract

Section: Introductionmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Motexafin gadolinium: a novel radiosensitizer for brain tumors

Francis¹,

Richards²,

Forouzannia

et al. 2009

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…An effective radiation-sensitizing agent enhances tumor cell death, while sparing the effects of radiotherapy on normal cells. MGd is a redox modulator that is selectively taken up by tumor cells [14]. MGd catalyzes the oxidation of intracellular reducing metabolites in a process known as futile redox cycling.…”

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

Treatment of Brain Metastases: Chemotherapy

Grimm

2011

Curr Oncol Rep

View full text Add to dashboard Cite

Although systemic therapy is the primary therapeutic modality for disseminated cancer, it plays a limited role in the treatment of brain metastases (BM). This review discusses the blood-brain barrier (BBB), interactions of systemic therapy with supportive care agents used in BM patients, the role of primary tumor sensitivity in the treatment of BM, and unique issues related to the specific primary tumor histologies. The specialized physiology of the brain vasculature that forms the BBB may preclude large and/or water-soluble systemic agents from reaching BM. Once metastases grow larger than 1-2 mm, there is preclinical and clinical evidence that the BBB is at least partially disrupted. Thus, the best treatment strategy in established BM may be to use an agent that is effective against the primary tumor regardless of its apparent BBB permeability. The use of anticonvulsants and corticosteroids must be carefully considered as they can decrease the effectiveness of systemic anti-tumor therapy. Despite the absence of level I data to routinely recommend the use of systemic therapy for solid tumor BM, these treatments should be considered in patients with good performance status and multiple, small metastases, especially if the primary tumor is chemosensitive. The systemic treatment of BM will continue to evolve as effective small-molecule inhibitors are developed and treatment regimens for each specific primary tumor are optimized.

show abstract